Opening book details…
Can I read Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer on EtoBox?
Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer by Yun-Hong Cheon; Moon Jin Kim; Min Gyu Kang; Hee Jin Kim; Sang Su Lee; Cha Young Kim; Dae-Hong Jeon; Yu Eun Kim; Gyeong-Won Lee is a Medicine article available to read on EtoBox.
What is Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer about?
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.
Who reads Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Yun-Hong Cheon; Moon Jin Kim; Min Gyu Kang; Hee Jin Kim; Sang Su Lee; Cha Young Kim; Dae-Hong Jeon; Yu Eun Kim; Gyeong-Won Lee
- Publisher
- Yonsei University College of Medicine; Yonsei University College of Medicine (KAMJE); Yonsei University; Seoul: Yonsei university College of medicine (ISSN 0513-5796)
- Published
- 2011
- Language
- EN
- Field
- Medicine (Health Sciences)